IL27 and pachyonychia congenita: To candidate IL30 as a target for personalized treatment of PC progression in patients with IL30 expressing tumor, we investigated its production by, and its effects on, human cancer cells derived from high-grade metastatic PC, by uncovering its potential to regulate PC driver genes, cancer immune escape mechanisms and its impact on host survival.